Softwr

Research · head to head

DNAnexus vs Suzy

DNAnexus logo

DNAnexus

Research

Regulated cloud platform for genomic and multiomic data, with GxP and FedRAMP coverage

From
On request
Rated
-
Full reviewWebsite
Suzy logo

Suzy

Research

Enterprise consumer insights on an owned US panel, resold elsewhere through Cint

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: DNAnexus no pricing is published, so an organisation cannot compare the total cost against running the same pipelines on its own cloud account until it is deep in a sales process.; Suzy the proprietary Crowdtap panel is US only at around a million consumers with roughly 50,000 verified active monthly, and everything international is resold Cint supply, so the speed and verification argument that justifies the price applies to one market.
  • They diverge on capability: DNAnexus covers Governed data storage, Suzy covers Suzy Insights.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which DNAnexus and Suzy actually diverge.

Attributes where DNAnexus and Suzy differ
AttributeDNAnexusSuzy
PlatformsWeb, LinuxWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in DNAnexus

  • Governed data storage
  • Workflow execution
  • App building
  • Controlled collaboration
  • Compliance posture
  • Cohort browsing

Only in Suzy

  • Suzy Insights
  • Suzy Live
  • Suzy Audiences
  • Suzy Speaks
  • Video open ends
  • Advanced methods
  • Data Explorer
  • AI Decision Engine

What people use each for

The jobs each tool is most often brought in to do.

DNAnexus

  • A clinical diagnostics laboratory that needs a CLIA and CAP aligned environment for production sequencing pipelines without building the compliance evidence itselfnot Suzy
  • A pharma sponsor analysing genomic endpoints in a registrational programme where 21 CFR Part 11 records are requirednot Suzy
  • A biobank or consortium giving hundreds of external researchers governed access to a dataset too large to distributenot Suzy
  • A diagnostics vendor packaging its pipeline as a versioned app so partner laboratories can run it without receiving the source codenot Suzy

Suzy

  • A US consumer packaged goods brand that needs concept testing back the same day because a packaging decision is due at the end of the week.not DNAnexus
  • An insights department running an always-on brand tracker on a US audience without re-commissioning fieldwork every wave.not DNAnexus
  • A team that wants quant screening followed immediately by moderated qual with the same respondents, rather than two vendors and two timelines.not DNAnexus
  • A product team testing claims and price sensitivity with MaxDiff and conjoint on a panel they can go back to repeatedly.not DNAnexus

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

DNAnexus

  • No pricing is published, so an organisation cannot compare the total cost against running the same pipelines on its own cloud account until it is deep in a sales process.
  • Compute and storage are billed through the platform rather than at underlying cloud list price, so the compliance envelope carries a persistent margin on every terabyte and core hour, which grows with the science rather than staying fixed.
  • Data egress at genomic scale is slow and chargeable, so leaving the platform later is a real project rather than a contract decision, and that gravity weakens negotiating position at renewal.
  • The regulated and validated configurations sit in a higher commercial tier than the research configuration, so an organisation that starts in research mode and later needs GxP faces a repricing rather than a setting change.
  • Bioinformaticians used to running Nextflow on their own infrastructure find the platform abstractions constraining, and porting an existing pipeline into the app model is engineering work that does not carry over to any other platform.

Suzy

  • The proprietary Crowdtap panel is US only at around a million consumers with roughly 50,000 verified active monthly, and everything international is resold Cint supply, so the speed and verification argument that justifies the price applies to one market.
  • Customers have asked Suzy to build proprietary panels with native speakers in Germany, France, Japan, India and Brazil, which confirms those do not exist today; multi-market brands need a second vendor and lose the single-source comparison.
  • Reviewers report the panel skews female and millennial and falls short on Gen Z, male and various ethnic segments, and that niche or B2B audiences are hard to reach, so quota fills can be slow or impossible.
  • Reviewers also raise data trust concerns about respondent sourcing and vetting, including one naming bot responses and acquiescence bias, which is the standing risk of any single owned opt-in panel with repeat respondents.
  • Pricing is a sales-led annual commitment reported to run around $88,000 a year at the median with onboarding fees and per-seat charges on top, with no trial, no self-serve and no pay-per-response option, so there is no cheap way to validate fit.
  • Credits are pre-committed monthly against forecast activity with no published overage rate, so under-use is wasted spend and a busy quarter triggers an unbudgeted purchase.
  • Integrations are genuinely thin: there is no public integrations page and no public API documentation, and the only confirmed external data relationship is Cint, so expect to move data by export.

Pricing, plan by plan

DNAnexus

On request
  • DNAnexus Platform$undefined/year
    • Quoted per organisation through a sales process
    • Storage and compute billed through the platform rather than at cloud list price
    • Regulated and validated configurations are a separate commercial tier

Suzy

On request
  • Suzy$undefined/year
    • Annual subscription with pre-committed monthly research credits
    • Credit volume set against forecast study activity
    • Onboarding fees and per-seat charges quoted separately

Which should you pick?

Choose DNAnexus if

  • You need governed data storage.
  • You work on Web, Linux.
  • You also want workflow execution.
DNAnexus review

Choose Suzy if

  • You need suzy insights.
  • You work on Web, iOS, Android.
  • You also want suzy live.
Suzy review

Questions people ask

Is DNAnexus or Suzy better?
Neither clearly leads. DNAnexus starts at On request and Suzy at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, DNAnexus or Suzy?
DNAnexus starts at On request and Suzy at On request.
Does DNAnexus or Suzy run on more platforms?
DNAnexus runs on Web, Linux. Suzy runs on Web, iOS, Android.
What is DNAnexus best used for?
DNAnexus is most often used for a clinical diagnostics laboratory that needs a clia and cap aligned environment for production sequencing pipelines without building the compliance evidence itself, a pharma sponsor analysing genomic endpoints in a registrational programme where 21 cfr part 11 records are required, a biobank or consortium giving hundreds of external researchers governed access to a dataset too large to distribute, a diagnostics vendor packaging its pipeline as a versioned app so partner laboratories can run it without receiving the source code. Of those, a clinical diagnostics laboratory that needs a clia and cap aligned environment for production sequencing pipelines without building the compliance evidence itself and a pharma sponsor analysing genomic endpoints in a registrational programme where 21 cfr part 11 records are required are not what Suzy is typically brought in for.
What can DNAnexus do that Suzy cannot?
DNAnexus covers Governed data storage, Workflow execution, App building, Controlled collaboration. Suzy covers Suzy Insights, Suzy Live, Suzy Audiences, Suzy Speaks.

Answered from the vendors’ own pages

DNAnexus: Why pay for DNAnexus instead of raw AWS?

For the compliance evidence. GxP, FedRAMP, CLIA, CAP and Part 11 coverage removes a validation programme most organisations would otherwise have to build and maintain themselves.

Suzy: Is the panel global?

No. Crowdtap, the owned panel, is US only. International studies run on Cint supply, which you could contract for directly.

DNAnexus: Is validated use included?

No. Regulated and validated configurations sit in a separate commercial tier from ordinary research use.

Suzy: What does it cost?

Nothing is published. Third-party analysis puts the median contract around $88,000 a year with a range roughly $34,000 to $187,500, plus onboarding and per-seat fees.

DNAnexus: Can I get my data out?

Yes, but egress at genomic scale is chargeable and slow, so plan exit costs at the point of signing.

Suzy: Is there an API?

Nothing public. Suzy publishes no API documentation and no named connectors beyond Cint. Verify any integration requirement in the sales call before committing.

DNAnexus: Does it host UK Biobank?

Yes, DNAnexus hosts the UK Biobank research analysis platform, which has its own access approval and cost terms.

Suzy: What changed in April 2026?

Suzy repositioned as an AI Decision Engine with Intelligence and Impact modules, while headcount fell from about 230 to 186. Ask how the roadmap is now split between that and the classic survey and qual products.

Share

Related pages

More on DNAnexus

More on Suzy

Keep looking

Other head to heads